This was assessed by testing the effect of trichostatin A (TSA), a histone deacetylase inhibitor, in non-expressing melanoma cells and in a cell clone harboring a methylated MAGEA1/hph construct, which allows selection (hygromycin resistance) of cells where activation of the transgene occurred. This evidence concerns the gene MAGEA1 and melanoma.